Circio Holding ASA, a biotechnology company developing next gen circular RNA vector technology for gene therapy, has entered a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles (LNPs) for tissue specific delivery of DNA-vectors to address genetic disease.     Under the collaboration, Certest has successfully performed packaging and in vitro validation of circVec-LNP formulations targeted for delivery to lung, liver and spleen, with positive technical r...